Mersana Therapeutics Inc (NASDAQ:MRSN) Expected to Announce Earnings of -$0.38 Per Share
Brokerages expect Mersana Therapeutics Inc (NASDAQ:MRSN) to post earnings per share (EPS) of ($0.38) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mersana Therapeutics’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.36). Mersana Therapeutics reported earnings per share of ($0.36) during the same quarter last year, which indicates a negative year over year growth rate of 5.6%. The firm is scheduled to announce its next earnings results on Thursday, August 13th.
On average, analysts expect that Mersana Therapeutics will report full-year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.07). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.16) per share, with EPS estimates ranging from ($1.33) to ($0.90). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.37 million. Mersana Therapeutics had a negative return on equity of 78.18% and a negative net margin of 6,099.64%.
Shares of NASDAQ:MRSN traded up $1.12 during midday trading on Thursday, reaching $23.40. 1,929,208 shares of the company’s stock traded hands, compared to its average volume of 1,426,101. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -16.71 and a beta of 2.79. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.59 and a current ratio of 4.59. Mersana Therapeutics has a one year low of $1.32 and a one year high of $24.07. The stock has a 50 day moving average of $17.06 and a 200 day moving average of $9.52.
In related news, Director Andrew A. F. Hack acquired 3,445,667 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The shares were purchased at an average price of $9.43 per share, with a total value of $32,492,639.81. Following the completion of the purchase, the director now directly owns 538,599 shares of the company’s stock, valued at $5,078,988.57. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Scott D. Sandell sold 20,914 shares of the stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $8.50, for a total value of $177,769.00. The disclosure for this sale can be found here. 5.30% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in MRSN. Marshall Wace LLP purchased a new stake in shares of Mersana Therapeutics during the first quarter worth about $141,000. California Public Employees Retirement System purchased a new stake in shares of Mersana Therapeutics during the fourth quarter worth about $147,000. Rhumbline Advisers grew its position in shares of Mersana Therapeutics by 5.6% during the fourth quarter. Rhumbline Advisers now owns 46,351 shares of the company’s stock worth $266,000 after purchasing an additional 2,448 shares in the last quarter. State Street Corp grew its position in shares of Mersana Therapeutics by 3.5% during the fourth quarter. State Street Corp now owns 620,685 shares of the company’s stock worth $3,557,000 after purchasing an additional 21,025 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Mersana Therapeutics by 27.6% during the 4th quarter. Acadian Asset Management LLC now owns 129,596 shares of the company’s stock valued at $742,000 after buying an additional 28,001 shares in the last quarter. Hedge funds and other institutional investors own 72.28% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Recommended Story: What is the definition of market timing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.